Platelet-to-high-density lipoprotein ratio (PHR) as a predictive biomarker for gastrointestinal cancers: evidence from NHANES (BMC Gastroenterology)

Emerging research suggests it might. A new analysis of NHANES data (2010–2018) involving over 19,000 participants reveals that a high platelet-to-HDL ratio (PHR)—a novel marker integrating inflammation and lipid metabolism—was independently associated with a threefold increase in gastrointestinal (GI) cancer risk. Participants in the highest PHR quartile were significantly more likely to have GI cancers, such as gastric, colorectal, and esophageal.